Rosalind Advisors, Inc., an investment firm, executed a notable transaction involving shares of Trevi Therapeutics Inc. The firm reduced its holding in the company by 46.10%.
This adjustment impacted Rosalind Advisors' portfolio by -1.65%. The firm's position in Trevi Therapeutics now represents 1.03% of its total holdings.
The transaction reflects a strategic shift in the investment approach of Rosalind Advisors towards the biopharmaceutical company. This reduction in stake was reported as of September 30, 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.